ストックスクリーナーアプリを入手
8.17
4.34%
0.34
前日終値:
$7.83
開ける：
$7.82
24時間の取引高:
1.32M
Relative Volume:
0.61
時価総額：
$848.84M
収益：
-
当期純損益:
$-294.51M
株価収益率:
-2.2949
EPS:
-3.56
ネットキャッシュフロー:
$-244.42M
1週間 パフォーマンス:
+17.05%
1か月 パフォーマンス:
-33.63%
6か月 パフォーマンス:
-76.48%
1年 パフォーマンス:
-67.08%
1日の値動き範囲:
$7.59
$8.22
1週間の範囲:
$6.755
$8.22
52週間の値動き範囲:
$6.36
$47.45
Dyne Therapeutics Inc Stock (DYN) Company Profile
DYN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
DYN
Dyne Therapeutics Inc
|
8.17 | 848.84M | 0 | -294.51M | -244.42M | -3.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Dyne Therapeutics Inc Stock (DYN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-12 | 開始されました | BMO Capital Markets | Outperform |
| 2025-03-07 | 開始されました | Scotiabank | Sector Outperform |
| 2024-12-13 | 開始されました | Robert W. Baird | Outperform |
| 2024-11-26 | 開始されました | RBC Capital Mkts | Outperform |
| 2024-10-24 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2024-05-21 | 繰り返されました | Chardan Capital Markets | Buy |
| 2024-04-30 | 開始されました | Morgan Stanley | Overweight |
| 2024-02-20 | 開始されました | H.C. Wainwright | Buy |
| 2023-02-27 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2023-02-15 | 開始されました | Oppenheimer | Outperform |
| 2023-01-26 | 開始されました | Guggenheim | Buy |
| 2022-07-20 | 開始されました | Chardan Capital Markets | Buy |
| 2022-07-12 | 開始されました | Raymond James | Outperform |
| 2020-10-12 | 開始されました | JP Morgan | Overweight |
| 2020-10-12 | 開始されました | Jefferies | Buy |
| 2020-10-12 | 開始されました | Piper Sandler | Overweight |
| 2020-10-12 | 開始されました | Stifel | Buy |
すべてを表示
Dyne Therapeutics Inc (DYN) 最新ニュース
More C-suite changes at Dyne - biocentury.com
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | DYN Stock News - GuruFocus
Dyne Therapeutics (DYN) Enhances Leadership Team with Key Appoin - GuruFocus
Dyne Therapeutics Announces Chief Business Officer and Chief Sci - GuruFocus
Dyne Therapeutics reshapes leadership team ahead of drug launches - Investing.com
Dyne Therapeutics Announces Chief Business Officer and Chief Scientific Officer Appointments - GlobeNewswire
Strategic C-Suite Expansion: Dyne Therapeutics Gears Up for Rare Disease Drug Launches - Stock Titan
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Dyne Therapeutics Reveals Strategic Compensation Plan: 330K Stock Options Granted - Stock Titan
Dyne wins new Outperform at BMO on prospects for lead drug - MSN
Insider Purchases Worth US$1.06m See Losses As Dyne Therapeutics Market Value Drops To US$770m - Yahoo
Myotonic Dystrophy Pipeline Analysis and Clinical Trials - openPR.com
RBC Cuts Price Target on Dyne Therapeutics to $36 From $41, Keeps Outperform, Speculative Risk - MarketScreener
FORCE platform boosts muscle function in dystrophic mice - BioWorld MedTech
Oversold Conditions For Dyne Therapeutics - Nasdaq
FORCE platform leads to Duchenne muscular dystrophy mouse model - BioWorld MedTech
BMO maintains Dyne Therapeutics stock with $50 target By Investing.com - Investing.com Canada
MDA 2025: DYNE-101 improves finger function in DM1 clinical trial - Muscular Dystrophy News
Dyne names Editas’ Erick Lucera CFO - biocentury.com
JPMorgan Seeks Clarity On Dyne Therapeutics' DYNE-101 Expansion, Regulatory Path - Benzinga
Sector Update: Health Care Stocks Steady Premarket Friday -March 21, 2025 at 09:24 am EDT - Marketscreener.com
JPMorgan cuts Dyne Therapeutics stock target to $17 from $18 By Investing.com - Investing.com Canada
Dyne Therapeutics Announces Appointment of Erick J. Lucera as Chief Financial Officer - The National Law Review
Dyne Therapeutics Appoints Erick Lucera as Chief Financial Officer - citybiz
Dyne Therapeutics names new CFO ahead of clinical milestones By Investing.com - Investing.com South Africa
Dyne Therapeutics Names Erick Lucera as CFO -March 20, 2025 at 05:36 pm EDT - Marketscreener.com
Dyne Therapeutics Appoints Erick Lucera as CFO - TipRanks
Dyne Therapeutics Announces Appointment of Erick J. Lucera As Chief Financial Officer - Marketscreener.com
Dyne Therapeutics names new CFO ahead of clinical milestones - Investing.com
Dyne Therapeutics Reports Inducement Grants Under Nasdaq - GlobeNewswire
New Dyne Therapeutics CFO Secures Major Equity Package Worth 280,600 Shares - StockTitan
Dyne Therapeutics Strengthens Commercial Launch Plans With Strategic CFO Appointment - StockTitan
(DYN) Technical Data - news.stocktradersdaily.com
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Financial Officer - The Globe and Mail
Dyne reports new long-term data from Phase 1/2 DELIVER trial of DYNE-251 - MSN
Stifel maintains Buy on Dyne Therapeutics with $66 target By Investing.com - Investing.com Canada
H.C. Wainwright maintains $46 target on Dyne Therapeutics stock By Investing.com - Investing.com Canada
H.C. Wainwright maintains $46 target on Dyne Therapeutics stock - Investing.com
Dyne Therapeutics Says Trial of Potential Duchenne Muscular Dystrophy Drug Shows 'Meaningful' Results - MarketScreener
Dyne Therapeutics (DYN) Gets a Buy from Scotiabank - The Globe and Mail
Dyne Therapeutics Announces New Long-Term Clinical Data - GlobeNewswire
Dyne : Phase 1/2 Trial Of DYNE-251 In DMD Shows Sustained Functional Improvements Through 18 Months - Nasdaq
Dyne Therapeutics Announces New Long-Term Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented and Sustained Functional Improvement Through 18 Months - The Manila Times
Dyne Therapeutics Reports Promising Long-Term Data for DYNE-251 in Duchenne Muscular Dystrophy with Plans for Accelerated Approval Submission - Nasdaq
Dyne Therapeutics, Inc. (NASDAQ:DYN) Given Average Rating of “Buy” by Brokerages - Defense World
BMO Capital Markets Begins Coverage on Dyne Therapeutics (NASDAQ:DYN) - Defense World
Dyne therapeutics chief commercial officer sells $1,733 in stock By Investing.com - Investing.com Australia
Dyne therapeutics chief commercial officer sells $1,733 in stock - Investing.com
Dyne Therapeutics chief scientific officer sells shares worth $24,501 By Investing.com - Investing.com South Africa
Dyne Therapeutics chief scientific officer sells shares worth $24,501 - Investing.com
GDX Is Looking To Retest 2020 Highs; Gold To 3K Soon? - The Globe and Mail
Dyne Therapeutics Inc (DYN) 財務データ
収益
当期純利益
現金流量
EPS
2.51%
大文字化:
|
ボリューム (24 時間):